

Anna Y. Belorusova Corresponding author(s): Emma Evertsson

Last updated by author(s): Oct 3, 2019

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

_					
C 1	1	١Ť١	ct	ŀι	CS
.)					l

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Con	firmed
	\boxtimes	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	\boxtimes	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes		A description of all covariates tested
\boxtimes		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes		Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
	'	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

MassLynx (v. 4.1, Waters) was used for controlling the Synapt G2-Si mass spectrometer for the acquisition of MS and MS/MS data.

Data analysis

ProteinLynx Global Server (v. 3.0, Waters) was used for processing MS/MS data. DynamX (v. 3.0, Waters) was used for the processing of HDX-MS data. The mean deuteration level per amino acid was calculated using Matlab (Mathworks). Pharmacological and SPR data was analysed using GraphPad Prism 8, Microsoft Excel and XLfit (ID Business Solutions). SIMCA 15 (Sartorius Stedim Data Analytics) was used for multivariate analysis. Modeling of in vivo data was done in Phoenix NMLE 1.3 (Certara). For the crystal structure determination, data sets were processed using Mosflm and Scala. Structures were solved by molecular replacement using programs form the CCP4 suite. Refinement was performed by manual rebuilding in Coot and automatic refinement using Refmac5 or CNS. PyMOL (Schrodinger LLC) was used for preparation of structural figures. For structural representation of HDX-MS data, missing loops were modelled with MOE (Chemical Computing Group Inc.).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Atomic coordinates and related structure factors have been deposited in the Protein Data Bank with accession codes: 6S4T (LXR\u00ed in complex with WAY-254011), 6S4U (LXR\u00ed in complex with AZ3), 6S4N (LXR\u00ed in complex with AZ6) and 6S5K (LXR\u00ed in complex with AZ8). All other data generated or analyzed during the study in this published article (and its supplementary information files) are available upon reasonable request.

Field-specific reporting							
Please select the or	Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.						
∑ Life sciences							
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf							
Life scier	nces stu	udy design					
All studies must disclose on these points even when the disclosure is negative.							
Sample size		s were chosen on the basis of standard practice performed for similar experiments and sethods were not used to predetermine sample sizes.					
Data exclusions		th an intensity lower than 5000, a mass error >5 ppm and present in less than two of the three data acquisitions were excluded DX-MS analysis. RNA samples with evidence of substantial degradation were excluded from the study.					
Replication	replicates were	-MS experiments were performed for one biological replicate (protein batch) and three technical replicates. Two to six biological icates were performed for pharmacological experiments. The number of replicates for each specific experiment is indicated ughout the manuscript text and figure legends.					
Randomization	descending ord	mals were randomized to receive the experimental drug or vehicle. HDX-MS samples were measured according to the time point in the cending order (longer deuteration times followed by shorter time points). Compounds were measured in a random order within the vidual time points.					
Blinding	No blinding of	blinding of experiments was required, as non of the experimental outcomes was based on (potentially biased) human judgment					
Reportin	g for si	pecific materials, systems and methods					
·	<u> </u>	about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,					
		your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.					
Materials & exp	perimental s	ystems Methods					
n/a Involved in th	ne study	n/a Involved in the study					
Antibodies		ChIP-seq					
Eukaryotic		Flow cytometry					
	Palaeontology MRI-based neuroimaging						
_	Animals and other organisms						
	earch participan	ts .					
Clinical dat	ā						
Eukaryotic c	ell lines						
Policy information	about <u>cell lines</u>						
Cell line source(s	line source(s) U2OS: ATCC, USA.						
Authentication		The cell line was unautheticated.					
Mycoplasma contamination		The cell line was regularly tested for absence of mycoplasma contamination.					
Commonly misidentified lines (See ICLAC register)		N/A					
Animals and	other or	zanisms					
Animals and		nyolving animals: ARRIVE guidelines recommended for reporting animal research					

Laboratory animals

Male 7-8 week C57BL/6J mice.

Wild animals

The study involved no wild animals.

Field-collected samples

The study involved no field collected samples.

Ethics oversight

Animal experiments were approved by the respective local animal ethics committees (Gothenburg region Local Ethics Review Committee on Animal experiments and University of Virginia Animal Care and Use Committee).

Note that full information on the approval of the study protocol must also be provided in the manuscript.